Concalls & earnings callsZydus Lifesciences Limited

Every summarised call, newest first. Latest is Q1 FY27, held 18 Aug 2026.

Latest quarter

Q1 FY27 snapshot

Zydus Lifesciences started FY27 with strong double-digit growth across all key businesses, driven by branded formulations in India, international markets, and strategic advancements in specialty and innovation.

Metric	This quarter	Change
Consolidated Revenue	₹8,020 Cr	22%
EBITDA Margin	24.1%	—
Net Profit	₹940 Cr	—
Net Debt to EBITDA	0.7 times	—

Latest guidance

Strong double-digit revenue growth for FY27.
India business to outperform market growth by 300-500 basis points.
EBITDA margin guidance of around 24% for FY27.
Full-year capex of ₹1,500-₹1,600 crores.
Medium-term target for branded portfolio to exceed two-thirds of total revenue.
US branded business contribution expected to cross 15% by year-end.

Said on the Q1 FY27 call.

Filed results

Reported quarterly history

From filed quarterly results. YoY and QoQ compare each metric on the same accounting basis.

Quarter	Revenue	Net profit (PAT)	Basic EPS
Q3 FY25	₹5,269.10 Cr+17% YoY+0.6% QoQ	₹1,026.20 Cr+29.9% YoY+11.5% QoQ	₹10.18+34.1% YoY+12.5% QoQ
Q2 FY25	₹5,237.00 Cr+19.9% YoY-15.6% QoQ	₹920.20 Cr+14.6% YoY-37.9% QoQ	₹9.05+14.3% YoY-35.9% QoQ
Q1 FY25	₹6,207.50 Cr+20.8% YoY+12.2% QoQ	₹1,482.50 Cr+30.8% YoY+19% QoQ	₹14.11+31.3% YoY+21% QoQ
Q4 FY24	₹5,533.80 Cr+10.4% YoY+22.8% QoQ	₹1,246.10 Cr+247.9% YoY+57.8% QoQ	₹11.66+295.3% YoY+53.6% QoQ
Q3 FY24	₹4,505.20 Cr+3.3% YoY+3.1% QoQ	₹789.90 Cr+25.1% YoY-1.7% QoQ	₹7.59+23.4% YoY-4.2% QoQ

Call history

18 Aug 2026
Q1 FY27Positive tone
Zydus Lifesciences started FY27 with strong double-digit growth across all key businesses, driven by branded formulations in India, international markets, and strategic advancements in specialty and innovation.
Consolidated Revenue
₹8,020 Cr22%
EBITDA Margin
24.1%
Pharmaceuticals & HealthcareVerified brief6 guidance items